Statistically significant improvements in lung function, symptoms and quality of life
36% reduction in rate of exacerbations over 24 weeks
Well tolerated safety profile over 48 weeks
NDA submission planned for 1H 2023
Conference call today at 8:30 a.m. EST / 1:30 p.m. GMT
Verona Pharma will host an investment community conference call at 8:30 a.m. EST / 1:30 p.m. GMT on Tuesday, December 20, 2022, to discuss the ENHANCE-1 results.
To participate, please dial one of the following numbers and ask to be placed into the Verona Pharma call:
+1-866-652-5200 for callers in the United States
+1-412-317-6060 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the ENHANCE-1 results press release will also be made available today on the Company’s website.
https://finance.yahoo.com/news/verona-pharma-announces-ensifentrine-meets-070000223.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.